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Abstract: A major challenge in the biomedical field is the creation of materials and coating strategies
that effectively limit the onset of biofilm-associated infections on medical devices. Biosurfactants
are well known and appreciated for their antimicrobial/anti-adhesive/anti-biofilm properties, low
toxicity, and biocompatibility. In this study, the rhamnolipid produced by Pseudomonas aeruginosa
89 (R89BS) was characterized by HPLC-MS/MS and its ability to modify cell surface hydrophobicity
and membrane permeability as well as its antimicrobial, anti-adhesive, and anti-biofilm activity
against Staphylococcus aureus were compared to two commonly used surfactants of synthetic origin:
Tween® 80 and TritonTM X-100. The R89BS crude extract showed a grade of purity of 91.4% and was
composed by 70.6% of mono-rhamnolipids and 20.8% of di-rhamnolipids. The biological activities of
R89BS towards S. aureus were higher than those of the two synthetic surfactants. In particular, the
anti-adhesive and anti-biofilm properties of R89BS and of its purified mono- and di-congeners were
similar. R89BS inhibition of S. aureus adhesion and biofilm formation was ~97% and 85%, respectively,
and resulted in an increased inhibition of about 33% after 6 h and of about 39% after 72 h when
compared to their chemical counterparts. These results suggest a possible applicability of R89BS as a
protective coating agent to limit implant colonization.
Keywords: biosurfactants; rhamnolipids; antimicrobial activity; biofilm dispersal; anti-adhesive/anti-biofilm
agents; HPLC-MS
1. Introduction
In the past decade, Staphylococcus aureus infections have been associated to an increase
in hospital stays and mortality and an economic burden estimated at USD 450 million [1,2].
This bacterial species is typically found in the human anterior nasopharynx and skin [3,4]
but it is also able to colonize tissue and artificial surfaces (prosthetic orthopedic implants,
heart valves, pacemakers, and vascular catheters), causing many acute and chronic per-
sistent infections [5,6]. It can be easily transmitted by direct contact or invasive medical
procedures [7,8] and is characterized by a notorious antibiotic recalcitrance, the ability to
produce aggressive toxins and virulence factors, and to develop biofilms [9,10]. In its sessile
form, S. aureus cells live as a structured community embedded in an extracellular polymeric
matrix, composed of protein, DNA, and polysaccharide. It can evade host defenses and
become tolerant to antimicrobials, making biofilm-associated infections particularly diffi-
cult to treat and eradicate [11–13]. When associated with medical devices, revision surgery
for replacement can be required as well as longer hospital stays, potentially secondary
infections, and implant removals may occur [14,15]. Biofilm formation begins with the
attachment of bacterial cells to human matrix proteins (collagen, fibronectin, and fibrino-
gen) covering the devices [12,15]. As consequence, the major challenge in the biomedical
field lies in designing new materials and coating strategies to retain bacterial attachment
and prevent biofilm formation. This can be obtained principally by modifying the physi-
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cal properties, such as hydrophobicity/hydrophilicity, texture, charge, and roughness, of
abiotic surfaces [10,14,16,17].
Surfactants are the compounds able to lower the interface tension between the sub-
stances, and act as detergents, wetting agents, forming agents and dispersants. Surfactants
are known to be amphiphilic, due to composing hydrophobic and hydrophilic moiety,
and they are classified as cationic, anionic, amphoteric, and non-ionic surfactants [18].
Surfactants have long been used in the cosmetic and food industries as well as in the medi-
cal field as cleansing and/or bactericidal solutions [19]. Surfactants can disrupt biofilms
themselves and/or perturb the process of their formation [20]. Tween® 80 (polysorbate 80)
and TritonTM X-100 are two non-ionic surfactants of synthetic origin, commonly used in lab-
oratories. Polysorbate 80 reduced Pseudomonas aeruginosa biofilm formation on medically
relevant materials, including contact lenses, at concentrations safe in humans [21]. More
recently, a combination of sub-minimal inhibitory concentration (sub-MIC) polymyxin B
and polysorbate 80 inhibited biofilm formation of the opportunistic multiple-drug-resistant
pathogen Stenotrophomonas maltophilia [22]. In addition, an inhibitory effect was demon-
strated on plastic, silicone, and dermal tissues on Methicillin-resistant S. aureus (MRSA)
biofilm formation, suggesting its effectiveness on tissues and foreign bodies as a washing
solution for wounds and/or pretreatment of indwelling catheters [20].
Similarly, the nonionic surfactant TritonTM X-100 has been extensively used for its
ability to destabilize both eukaryotic and prokaryotic membranes [23,24]. Its toxicity
derives from the disrupting action of its polar head group on the hydrogen bonding
present within the cell’s lipid bilayer, leading to the destruction of the compactness and
integrity of the lipid membrane [25]. TritonTM X-100 has also been demonstrated to induce
autolysis by increasing bacteria susceptibility to antibiotics [26,27] and to affect the structure
and physiological aspects of biofilms by decreasing the carbohydrate and protein content
in the extracellular polymeric substances (EPS) [28].
Among surfactants, biosurfactants (BSs) may represent ideal natural candidates to
inhibit the contamination of medical devices by microbial pathogens. In the last decade, a
large number of publications has described their anti-adhesive and anti-biofilm properties
as coating agents on implantable devices preserving their biocompatibility [29–31]. The
commercial success of these natural compounds, however, is related to their ability to
exhibit equal or superior performance over chemicals. Biosurfactants are characterized
by a series of advantages such as low toxicity, high biodegradability, great environmental
compatibility, good foaming properties, and stable activity at extreme pH [31–33]. Other
advantages are the possibility of producing them on renewable media at low cost and
of modifying their chemical composition (for example, by means of genetic engineering
applied to producing microorganisms) to meet specific functional needs [31,34,35].
These amphiphilic molecules of microbial origin share a pronounced surface activity
leading to a reduction of surface tension at the interfaces of phases with dissimilar po-
larities (liquid–air, liquid–liquid, or liquid–solid) [36,37]. Among them, rhamnolipids are
particularly important for applications in the biomedical and technological fields [30,31].
They are mainly produced by P. aeruginosa strains and are constituted by a complex mixture
of congeners comprising either one (for mono-rhamnolipids) or two (for di-rhamnolipids)
molecules of rhamnose glycosidically linked to a dimer of 3-hydroxy fatty acids varying
in chain length [38]. The rhamnolipids biosynthetic pathway is distinguished in three
major steps [39]. In the first step, the β-hydroxy fatty acids are fused, then two special
rhamnosyltransferases sequentially catalyze the condensation of the fatty acid precursors
to mono and di rhamnolipids.
The congener distribution has been shown to be mostly strain-dependent but can also
be dependent on the growth phase of the culture [39] and on the carbon source used [40].
Rhamnolipids varying in alkyl chain length and rhamnose molecules number have
a different hydrophilic-lipophilic balance (HLB) values and therefore may contribute
differently on the emulsification properties of the mixture of surfactants.
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For the effective evaluation of the rhamnolipids as surfactants, the exact ratio of mono-
and di- congeners and the composition in alkyl chains must be known. High-performance
liquid chromatography coupled with tandem mass spectrometry (HPLC-MS/MS) is by far
the most accurate method for rhamnolipids identification and quantitation [41–44].
For this reason, in this work, the precise chemical composition and purity of rham-
nolipids mixtures produced during the fermentation process has been defined using the
HPLC–MS/MS technique.
Then, rhamnolipid R89BS was compared with the chemical surfactants Tween® 80
and TritonTM X-100 to investigate its ability to modify cell surface hydrophobicity and
membrane permeability and to evaluate its effectiveness as antimicrobial, anti-adhesive,
and anti-biofilm agents against S. aureus.
2. Materials and Methods
2.1. Chemicals and Materials
All solvents and reagents were analytical or the highest grade available. Hydrochloric
acid, methanol, acetone, ethanol, and dichloromethane were purchased from Merck (Darm-
stadt, Germany). Formic and acetic acid, chloroform, and ethyl acetate were purchased
from Sigma Aldrich (Milan, Italy). Acetonitrile was purchased from Carlo Erba Chemi-
cals (Rodano, Milan, Italy). Water analytical grade was obtained by ultrafiltration with
Elga PureLab Ultra, (M Medical, Cornaredo, Milan, Italy). Triton™ X-100 and Tween® 80
(nonionic surfactants) were purchased from Sigma Aldrich (Milan, Italy).
2.2. Bacterial Strains
The biosurfactant-producing strain P. aeruginosa 89 was stored at −80 ◦C in Tryptic Soy
Broth (TSB) (Biolife Italiana, Monza, Milan, Italy) with 25% glycerol (Scharlab, Barcelona,
Spain). The biofilm producer strain S. aureus ATCC® 6538TM was stored at −80 ◦C in TSB
with 25% glycerol.
2.3. Biosurfactant Production
Biosurfactant R89 (R89BS) was produced and extracted as described by Ceresa et al. [45].
Briefly, P. aeruginosa 89 was grown in Nutrient Broth II (Sifin, Berlin, Germany) at 37 ◦C for
4 h at 140 rpm. Afterwards, 24 mL of this culture were transferred in 1.2 L of Siegmund-
Wagner medium and incubated at 37 ◦C for 3, 5 and 6 days at 120 rpm. Acidified free-cell
supernatant was stored overnight at 4 ◦C and R89BS extracted three times with ethyl
acetate. Then, solvent was evaporated to dryness under vacuum condition and the raw
biosurfactant was weighed for yield calculation.
2.4. Samples Purification
Rhamnolipid standards used for quantitative analysis and for the biological assays
were obtained by purification from the crude extract according to the method reported by
Rudden et al. [43] and modified as follows.
The R89BS biosurfactant extract was chromatographed on a silica gel (230–400 mesh;
Merck KGa) column. Elution was carried out with dichloromethane and then with
dichloromethane/methanol mixture with methanol gradually increased from 5 to 60%.
The process was monitored by thin layer chromatography (TLC) that was carried out on
precoated silica gel 60 F254 plates (Merck Co., Inc., Damstadt, Germany). TLC plates, spot-
ted with the purified biosurfactant samples dissolved in methanol, were developed using
chloroform/methanol/water, 70:28:2 as the mobile phase, and were visualized by spraying
plats with non-specific reagent (sulfuric acid/p-anisaldehyde/acetic acid, 1:0.6:50).
The purified fractions contained either only mono-rhamnolipids congeners (fraction
I—mR89BS) or only di-rhamnolipids congeners (fraction II—dR89BS). Each fraction was
analyzed by LC-MS/MS to determine exact sample composition and each congener was
quantified based on the percentage peak area of total rhamnolipids samples (no commercial
standards are currently available).
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For the LC-MS/MS analysis, an aliquot of the crude biosurfactant extract or of the
purified fractions was dissolved in methanol to obtain a 1 mg/mL stock solutions. Working
standard solutions were prepared by diluting the stock solutions with methanol to a series
of proper concentrations. The standard stock solutions and the working standard solutions
were all stored at 4 ◦C.
2.5. LC-MS/MS
A Surveyor HPLC on line with a LCQ DECA XP Plus (Thermo Finnigan, San Jose’,
USA) Ion Trap mass spectrometer equipped with an ESI source was employed. For
separation, reversed-phase chromatography on an analytical Sinergy Hydro 5 µm C18,
150 × 2 mm column (Phenomenex, Torrance, CA, USA) protected with a C18-Security
Guard cartridge, 4 × 2.0 mm (Phenomenex) was used at 30 ◦C. The flow rate was set to
0.4 mL/min. Mobile phase gradient consisting of 10 mmol/L aqueous ammonium formate
buffer at pH 4.2 (A) and acetonitrile (B) was used. The gradient was set to 40% B from 0
to 4 min, increased to 80% B from 4 to 20 min then 90% B from 20 to 26 min, and then it
decreased to 40% in 5 min and remained constant for equilibration. The total run time was
36 min. The injection volume was 5 µL.
The mass spectrometer was equipped with an ESI source operating in negative ion
mode. The ESI-MS and ESI-MS/MS spectra of the rhamnolipids were recorded using direct
infusion of each rhamnolipids solution and the optimal values for ESI source parameters
were determined as follows. Source voltage and capillary voltage were at 5.0 kV and −18 V.
The capillary temperature was maintained at 300 ◦C, and nitrogen was used as nebulizing
gas at 50 arbitrary units and 7 arbitrary units as auxiliary gas flow. Data were acquired
in negative MS total ion scan mode (mass scan range m/z 100–1000) and MS/MS product
ion scan mode with normalized collision energy (nce%) optimized for each precursor ion
selected: m/z 475, 531, and 649, 27%, 503, 25%, 677, 29%, and 621, 31%.
LC-ESI-MS/MS in multiple reaction monitoring (MRM) modalities were applied to
the selected precursor ions, following the conditions set during the infusion analysis mode.
Data were acquired in negative modality.
2.6. Rhamnolipids Quantification
Quantitative analyses were performed considering the amount of mono- and di-
rhamnolipids congeners present in the purified mR89BS (fractions I) and dR89BS (fraction
II), respectively. Each fraction was used as a reference standard: mR89BS as a reference
standard of mono-rhamnolipids, dR89BS as a reference standard of di-rhamnolipids.
Calibration curves were measured in triplicate in a range of 1–50 µg/mL (n = 5) for
each reference fraction (I and II). The limit of detection (LOD) and limit of calculation
(LOQ) were determined from the signal-to noise ratios (S/N) with S/N of 3 or greater
for LOD and S/N of 10 or greater for LOQ. S/N was calculated for the more abundant
congeners of fraction I and II (Rha-C10-C10 and Rha-Rha-C10-C10, respectively).
2.7. Determination of Critical Micelle Concentration
Critical micelle concentrations (CMCs) of R89BS extract and purified fraction I and II
(mR89BS, dR89BS) were obtained by measuring the surface tension of aqueous biosurfac-
tant solutions from 0.017 to 1 mg/mL. The measurements were carried out at 25 ◦C with a
ring tensiometer (KSV Sigma 703D, KSV Instruments Ltd., Espoo, Finland) according to
the Du-Nouy ring method. The value of CMC was defined as the intersection point of the
straight lines extrapolated from the curve plotted between biosurfactant concentration and
surface tension [46].
2.8. Stability Study
The effect of the heat/cold treatments on R89BS solutions (0.5, 1, 2 mg/mL) was
evaluated by measuring surface tension and emulsification index at 24 h (E24%) after
treatment at 100 ◦C for 1 h and at −80 ◦C for 24 h. To investigate the pH stability, R89BS
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solutions at pH ranging from 3.0 to 11.0 were prepared. Afterwards, the surface tension
and E24% were measured [46].
2.9. Antimicrobial Activity (Co-Incubation Assay)
The evaluation of the antibacterial action of synthetic and microbial surfactants against
planktonic cells of S. aureus® 6538TM was carried out following the protocol of Wiegand et al. [47].
The R89BS stock solution was prepared in phosphate-buffered saline (PBS). The stock
solutions of purified fraction I and II (mR89BS, dR89BS) and of synthetic surfactants
(Tween® 80, TritonTM X-100) were prepared in PBS at a concentration corresponding to
HPLC-MS grade rhamnolipids in R89BS extract. The tested concentrations ranged from
0.03 to 2 mg/mL. S. aureus (5 × 105 colony forming unit (CFU)/mL) was grown in Mueller
Hinton broth (Sifin, Berlin, Germany) in the presence of surfactants solutions (test wells)
or PBS (wells of positive control of growth). Vancomycin (Sigma-Aldrich, Milan, Italy)
at 1µg/mL was used as a reference (wells of negative control of growth). Plates were
incubated at 37 ◦C for 16–20 h. Assays were conducted in triplicate and repeated in two
independent experiments (n = 6).
The MIC of surfactants was defined as the lowest concentration of surfactants that
inhibits visible growth of S. aureus as observed with the unaided eye.
2.10. Cell Surface Hydrophobicity
Bacterial suspension was prepared in PBS to obtain an optical density (OD) at 600 nm
of 0.5, treated with the surfactants at their MIC and incubated at 37 ◦C for 1 h at 150 rpm.
Untreated suspension was taken as control. Cell hydrophobicity was measured by micro-
bial adherence to hexadecane (Scharlab, Barcelona, Spain) according to Rosenberg et al. [48].
Microbial cells were collected by centrifugation at 4000 rpm for 15 min and resuspended in
PUM buffer, pH 7.1 (22.2 g K2HPO4·3H2O, 7.26 g KH2PO4, 1.8 g urea, 0.2 g MgSO4·7H2O
and distilled water to 1 L). One milliliter of hexadecane was mixed to 4 mL of cell suspen-
sions in a glass tube at high speed for 2 min and equilibrated for 10 min. Afterward, the
OD of the initial cell suspensions and aqueous phases were measured at 550 nm (Genova
Plus, Jenway, UK) and cell hydrophobicity was calculated as indicated by Ceresa et al. [49].
Assays were performed in triplicate and repeated in two independent experiments (n = 6).
2.11. Cell Membrane Permeability
Bacterial suspension was prepared in PBS to obtain an OD at 600 nm of 0.5, treated
with the surfactants at their MIC and incubated at 37 ◦C for 1 h at 150 rpm. Untreated
suspension was taken as control. Cell membrane permeability was evaluated by checking
crystal violet enhanced penetration. Cells were collected by centrifugation at 4000 rpm for
15 min, resuspended in PBS containing crystal violet (10 µg/mL) and incubated at 37 ◦C at
150 rpm for 20 min. Cells were collected by centrifugation at 4000 rpm for 15 min and the
absorbance of the initial crystal violet (CV) solution and sample solutions was measured
at 590 nm (Genova Plus, Jenway, UK). Afterwards, the percentage of crystal violet uptake
was calculated as indicated by Ceresa et al. [49].
Assays were performed in triplicate and repeated in two independent experiments (n = 6).
2.12. Inhibition of Bacterial Adhesion, Biofilm Formation and Disruption of Mature Biofilm
on Silicone
2.12.1. Medical-Grade Silicone
Silicone elastomeric discs (SEDs) of two different sizes (10 mm in diameter and 1.5 mm
in thickness and 8 mm in diameter and 1.5 mm in thickness) were cut from medical-grade
silicone sheets (TECNOEXTR s.r.l, Palazzolo sull’Oglio, Italy) and prepared according to
Ceresa et al. [46]. Briefly, SEDs were cleaned with a 1.4% (v/v) RBSTM 50 solution (Sigma-
Aldrich, Milan, Italy), sonication for 5 min at 60 kHz (Elma S30H, Elmasonic) and two
rinses in MilliQ water. Then, SEDs were further sonicated in methanol (99%), rinsed twice,
sterilized by autoclaving, and dried at 37 ◦C for 20 h.
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2.12.2. Biofilm Dispersal Activity (Co-Incubation Assay)
Experiments were carried out in 24 well-plates as described by Ceresa et al. [45].
Briefly, SEDs (10 mm in diameter and 1.5 mm in thickness) were moved aseptically into the
plates and incubated with 1 mL S. aureus® 6538TM culture (1 × 107 CFU/mL in TSB + 1%
glucose) at 37 ◦C in static condition for 24 h. Blank silicone surfaces (without biofilm) were
also included in the experimental setting.
The formed biofilms were then incubated in the presence of surfactants solutions
(test SEDs) or PBS (control SEDs) for 24 h. The tested surfactants concentrations ranged
from 0.06 to 2 mg/mL. At the end of the incubation time, biofilms were washed twice,
and their metabolic activity was evaluated by the MTT [3-(4,5-dimethylthiazolyl-2-yl)-
2,5-diphenyltetrazolium bromide] reduction assay. Biofilms still present on the surface
of SEDs were dipped in 1 mL MTT working solution (0.3% MTT (Sigma-Aldrich), 0,01%
glucose, 1 µM menadione (Sigma-Aldrich)) for 30 min at 37 ◦C. Formazan crystals were
dissolved with a solution DMSO/0.1 M glycine buffer (pH 10.2) (7:1). Absorbance at
570 nm (A570) was measured (Victor3VTM, Perkin Elmer, Milan, Italy) and the percentage
of biofilm dispersal was calculated. Assays were conducted in triplicate and repeated in
two independent experiments (n = 6).
2.12.3. Anti-Adhesive Activity (Deposition Assay)
SEDs surface (8 mm in diameter and 1.5 mm in thickness) coating with the BSs was
carried out as described by Ceresa et al. [49], with minor changes. Briefly, a volume of
30 µL of surfactants solutions (R89BS: 2 mg/mL; TRITONTM X-100, TWEEN ® 80, mR89BS
and dR89BS: at a concentration corresponding to HPLC–MS grade rhamnolipids in R89BS
extract) or an equal volume of PBS as control, were deposited on the silicone surfaces.
SEDs were then placed under laminar flow to allow complete drying and, subsequently,
moved into 48-well plates. The discs were filled with 0.5 mL of a S. aureus suspension
(107 CFU/mL in TSB +1% glucose) and incubated at 37 ◦C for 6 h. Blank silicone surfaces
(without adherent cells) were also included in the experimental setting.
The quantification of adherent cells was carried out by CV staining. SEDs were filled
with 0.5 mL of a 0.2% CV solution for 10 min at room temperature. Afterwards, adherent
cells were dissolved with 0.5 mL of 33% acetic acid and A570 was measured. The assays
were carried out in triplicate and repeated in two independent experiments (n = 6).
2.12.4. Anti-Biofilm Activity (Pre-Coating Assay)
Experiments were carried out as described by Ceresa et al. [45]. Briefly, SEDs (10 mm
in diameter and 1.5 mm in thickness) were moved aseptically into 24-well plates. Surfactant-
coated SEDs were obtained by immersion in 1 mL of surfactant solutions (R89BS: 2 mg/mL;
TRITONTM X-100, TWEEN® 80: at a concentration corresponding to HPLC–MS grade
rhamnolipids in R89BS extract) or PBS as control at 37 ◦C for 24 h at 180 rpm. Subsequently,
surfactants solutions or PBS were aspirated, SEDs were moved to new plates and dried
under a laminar flow.
Surfactant-coated SEDs and control SEDs were incubated at 37 ◦C in static conditions
with 1 mL S. aureus® 6538TM culture (1 × 107 CFU/mL in TBS + 1% glucose). Blank silicone
surfaces (without biofilm) were also included in the experimental setting.
Every 24 h, SEDs were transferred onto new plates containing fresh media. The
anti-biofilm effect of surfactant-coated SEDs was quantified at different timepoints (24 h,
48 h, 72 h) by CV staining. Biofilms were washed twice, dried and stained with 1 mL of CV
solution (0.2%) for 10 min. The dye was solubilized in acetic acid (1 mL, 33%), A570 was
measured, and the percentages of biofilm inhibition were calculated.
In addition, the efficacy of purified mono-rhamnolipids congeners (fraction I—mR89BS)
and di-rhamnolipids congeners (fraction II—dR89BS) was evaluated at 72 h. BSs-coated
SEDs were obtained by immersion in 1 mL of mR89BS and dR89BS solutions (at a concen-
tration corresponding to HPLC–MS grade rhamnolipids in R89BS extract). Biosurfactant-
coated SEDs and control SEDs were incubated at 37 ◦C in static conditions with 1 mL
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S. aureus® 6538TM culture (1 × 107 CFU/mL in TBS + 1% glucose) for 72 h. Every 24 h,
SEDs were transferred into new plates containing fresh media. The anti-biofilm effect of
surfactant-coated SEDs was quantified by CV staining.
Assays were conducted in triplicate and repeated in two independent experiments (n = 6).
2.13. Statistical Analysis
All analyses and graphs were performed using the statistical program R, 3.6.2 (R Core
Team, 2019). One-way ANOVA, followed by Tukey post hoc test was used to analyse the
data obtained in the assays for the evaluation of the activity of surfactants on cell surface
hydrophobicity, cell membrane permeability, adhesion, and biofilm formation. Two-way
ANOVA, followed by Tukey post hoc test was performed to compare the results obtained
from the biofilm dispersal assay and anti-biofilm tests. Results were considered to be
statistically significant when p < 0.05.
3. Results
3.1. Chemical Characterization
Rhamnolipids are produced as a heterogeneous mixture of mono- and di-rhamnolipids
varying in the fatty acid chain length. Mono-rhamnolipids contain one rhamnose moiety
whereas di-rhamnolipids contain two rhamnose moieties, connected to two B-hydroxyl
acids (Figure 1a,b).
Figure 1. Structure of mono-rhamnolipids (a) and di-rhamnolipids (b); n = 4–8 methylene group for
a chain length of C8–C12.
Product ion spectra obtained in tandem mass spectrometry, performed in electrospray
ionization (ESI-MS/MS) in negative modality, were used for identification of rhamnolipids
and to define the structure of the homologues. The cleavage between the two B-hydroxy
fatty acids produce structure informative and complementary fragments.
The mono-rhamnolipid family was composed by five members corresponding of
Rha-C10-C10, Rha-C8-C10 and Rha-C10-C8, Rha-C10-C12, and Rha-C12-C10 homologues,
whose structures were confirmed by the product ion spectra of the precursor molecules
[M–H]− at m/z 503, 475, and 531, respectively.
Mono-rhamnolipid Rha-C10-C10, precursor molecules [M–H]− at m/z 503 shows a
product ion spectrum with fragment [Rha-C10]− (m/z 333) after cleavage of the terminal
B-hydroxy fatty acid. Further fragmentation is [C10-C10]− (m/z 339) (Figure 2a). Mono-
rhamnolipids Rha-C10-C8 and Rha-C8-C10, precursor molecule [M–H]− at m/z 475 show
a product ion spectrum with fragment [Rha-C10]− (m/z 333) or [Rha-C8]− (m/z 305) after
cleavage of the terminal B-hydroxy fatty acid. Further fragmentation is [C10-C8]−/[C8-
C10]− (m/z 311). Mono-rhamnolipids Rha-C12-C10 and Rha-C10-C12, precursor molecule
[M–H]− at m/z 531 show a product ion spectrum with fragment [Rha-C12]− (m/z 361)
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or [Rha-C10]− (m/z 333) after cleavage of the terminal B-hydroxy fatty acid. Further
fragmentation is [C12-C10]−/[C10-C12]− (m/z 367).
The di-rhamnolipid family was represented by three main members corresponding
Rha-Rha-C10-C10, Rha-Rha-C10-C12, and Rha-Rha-C12-C10 homologues, whose structures
were confirmed by the product ion spectra of the deprotonated molecules [M–H]− at m/z
649 and 677, respectively.
Di-rhamnolipid Rha-Rha-C10-C10, precursor molecule [M–H]− at m/z 649 shows
a product ion spectrum with fragment [Rha-Rha-C10]− (m/z 479) after cleavage of the
terminal B-hydroxy fatty acid. Further fragmentation is [C10-C10]− (m/z 339) (Figure 2b).
Di-rhamnolipids Rha-Rha-C12-C10 and Rha-Rha-C10-C12, precursor molecule [M–H]−
at m/z 677 shows a product ion spectrum with fragment [Rha-Rha-C12]− (m/z 507) or
[Rha-Rha-C10]− (m/z 479) after cleavage of the terminal B-hydroxy fatty acid. Further
fragmentation is [C12-C10]−/[C10-C12]− (m/z 367).
LC-ESI-MS/MS analysis was set up to analyse purified fraction I (mR89BS), purified fraction
II (dR89BS), and R89BS crude extracts. Table 1 summarises the MRMs experimental conditions
obtained during the set up and subsequently used for the quantification studies. In mR89BS
the deprotonated ion at m/z 503 corresponds to Rha-C10-C10, the most abundant congener
(90.1%) of the total of the sample. In dR89BS the deprotonated ion at m/z 649 corresponds to
Rha-Rha-C10-C10, the most abundant congener (96.8%) of the total of the sample.
Figure 2. Product ion spectra and proposed fragmentation of (a) m/z 503 [M–H]− of Rha-C10-C10
and (b) m/z 649 [M–H]− of Rha-Rha-C10-C10.
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Rha - C10 - C8/C8 - C10 10.18 475 305, 333, 311 (27) 2.8
Rha - C10 - C10 14.54 503 333, 339 (27) 90.1
Rha - C12 - C10/C10 - C12 18.32 531 333, 361, 367 (27) 7.1
Total 100
dR89BS (fraction II)
Rha - Rha - C10 - C10 12.12 649 339, 479 (28) 96.9
Rha - Rha - C10 - C12/C12 - C10 15.65 677 507, 479, 367 (29) 3.1
Total 100
1 nce%: normalized collision energy.
In Figure 3 mono- and di-rhamnolipids congeners of R89BS crude extract are sepa-
rated according to the following Rt as reported in Table 1. Mono-rhamnolipids Rt were
10.18, 14.54, 18.32 min and di rhamnolipids Rt were 12.12 and 15.65 min, respectively.
Differentiation on constitutional isomers (Rha-C10-C8 and Rha-C8-C10, Rha-C10-C12 and
Rha-C12-C10, Rha-Rha-C10-C12 and Rha-Rha-C12-C10) were not possible to separate using
chromatography but can be achieved by means of MS/MS experiment.
Figure 3. LC-MS/MS mass chromatogram of R89BS crude extract. Mono-rhamnolipids with [M–H]−
at m/z 475 (a), 503 (b), 531 (c). Di-rhamnolipids with [M–H]− at m/z 649 (d) and 677 (e).
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3.2. Rhamnolipids Quantification
Purified fraction I (mR89BS) and purified fraction II (dR89BS) were used as reference
standard of mono-rhamnolipid and di-rhamnolipids quantification, respectively. Mono-
rhamnolipids fraction, represented by congener with pseudo molecular ions [M-H]− 475,
503, 531 m/z was used for the construction of mono-rhamnolipids calibration curve injecting
five different concentration levels and analysing in triplicate. It showed a good linearity in
the range 1–50 µg/mL. LOD and LOQ were evaluated for the more abundant congener of
the fraction, Rha-C10-C10, and were found to be 0.05 and 0.1 µg/mL.
Di-rhamnolipids fraction, represented by congener with pseudo-molecular ions [M-
H]− 649, 677 m/z was used for the construction of di-rhamnolipids calibration curve
injecting five different concentration levels and analysing in triplicate. It showed a good
linearity in the range 1–50 µg/mL. LOD and LOQ were evaluated for the more abundant
congener of the fraction, Rha-Rha-C10-C10, and were found to be 0.05 and 0.1 µg/mL.
The method was applied for the quantitation and comparison of rhamnolipids con-
geners present in R89BS crude extracts obtained at different incubation times. Table 2 shows
the concentrations of rhamnolipids congeners obtained after 3-, 5-, and 6-days incubation
time. The higher amount of rhamnolipids congeners produced (91.4% of the entire extract)
was obtained after 5 days incubation time, against 55.8% after 3 days and 76.8% after 6 days.
In all extracts, Rha-C10-C10 (MW 504 Da) and Rha-Rha-C10-C10 (650 Da) are the most
abundant congeners, while the mono-rhamnolipids family represents the more abundant
family (varying from 59.7 to 77.2%).
The grade of purity of the R89BS crude extract obtained with 5 days incubation was
91.4% and was composed by 70.6% of mono-rhamnolipids and 20.8% of di-rhamnolipids.
R89BS crude extract and its purified mR89BS and dR89BS were tested for anti-adhesive
and anti-biofilm assays.
Table 2. Concentrations of rhamnolipids congeners in R89BS crude extracts at different incubation










Rha-C10-C8/C8-C10 9.22 (0.93) 19.53 (1.93) 14.93 (1.34)
Rha-C10-C10 299.93 (15.12) 635.88 (33.70) 485.48 (23.64)
Rha-C12-C10/C10-
C12 2.84 (0.25) 50.55 (5.35) 38.59 (3.72)
Total 311.99 705.96 539.00
Di-rhamnolipids
Rha-Rha-C10-C10 217.80 (17.21) 201.67 (16.34) 205.20 (16.22)
Rha-Rha-C10-
C12/C12-C10 7.21 (0.71) 6.67 (0.88) 24.13 (2.97)
Total 225.01 208.34 229.33
Total rhamnolipids 537.00 914.30 768.33
1 sd: standard deviation.
3.3. Determination of Critical Micelle Concentration and Stability Study
At pH 7.0, the condition adopted in anti-biofilm assays, the experimental results
revealed that the surface tension of alkaline distilled water decreased rapidly as the con-
centration of biosurfactant increased with a minimum surface tension of 29.65 mN/m,
29.32 mN/m, and 34.76 mN/m for the R89BS crude extract, purified fraction I (mR89BS),
and purified fraction II (dR89BS), respectively.
CMC values for R89BS, mR89BS, and dR89BS were found at 0.0563 mM, 0.0606 mM,
and 0.0461 mM, respectively.
In addition, it was observed that R89BS solutions retained their surface activity over
a wide pH range and heat treatments. In particular, at the pH range from 3.0 to 11.0,
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the surface tension is preserved without significant variations with an average value of
30.64 ± 0.30 mN/m. On the contrary, E24h% is not altered to pH values between 7.0 and
11.0, showing just over 60%, but it is zero from pH 6.0 at pH 3.0 (Table S1). The treatments at
100 ◦C for 1 h and at −80 ◦C for 24 h did not cause any particular changes in surface tension
and emulsion index compared to the values obtained with R89BS solutions maintained at
room temperature (20 ◦C) and used as a control.
3.4. Antimicrobial Activity
To evaluate and compare the antimicrobial activity of R89BS, mR89BS, dR89BS, TritonTM
X-100 and Tween® 80, bacterial planktonic cells were treated with different concentrations of
the five surfactants for 16–20 h. An antibacterial activity against S. aureus® 6538TM planktonic
cells was found for R89BS, mR89BS and TritonTM X-100. MIC values for these surfactants were
identified in the concentration of 0.06 mg/mL, 0.03 mg/mL, and 0.22 mg/mL respectively. On
the contrary, no MIC was detected for dR89BS and Tween® 80.
3.5. Cell Surface Hydrophobicity and Cell Membrane Permeability
Cell surface hydrophobicity and cell membrane permeabilization studies were per-
formed by treating S. aureus® 6538TM with surfactants at their MIC: for this reason, dR89BS
and Tween® 80 were excluded from these assays. As shown in Figure 4a, there were
significant differences in S. aureus® 6538TM surface hydrophobicity (CSH) between control
samples and bacterial cells incubated with R89BS, mR89BS, and TritonTM X-100 MIC con-
centrations (p < 0.001). In particular, the treatment with these three surfactants induced
a decrease of CSH from 99.8% (control samples) to 1% for mR89BS, 7% for R89BS, and
4.8% for TritonTM X-100. Furthermore, significant changes in S. aureus cell membrane
permeability were also observed for the three surfactants (p < 0.001) with an increase in
crystal violet uptake from 32.8% (control samples) to 62.2% for TritonTM X-100, 83.6% for
R89BS and 84.9% for mR89BS (Figure 4b).
Figure 4. Changes in surface hydrophobicity and crystal violet uptake induced by surfactants.
Surface hydrophobicity (a) and crystal violet uptake (b) of S. aureus® 6538TM cells treated with
natural (R89BS, mR89BS) and chemical surfactants (TritonTM X-100), compared to control samples.
3.6. Biofilm Dispersal
To evaluate the effect of surfactants against sessile cells, biofilms were co-incubated
for 24 h with different concentrations of R89BS, mR89BS, dR89BS, TritonTM X-100 and
Tween® 80. All the tested surfactants were able to dislodge S. aureus® 6538TM pre-formed
biofilms (Figure 5). R89BS, dR89BS, TritonTM X-100 and Tween® 80 are ineffective at the
concentration of 0.06 mg/mL but promoted biofilm dispersal at concentrations from 0.12 to
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2 mg/mL with a reduction of the biofilm metabolic activity in a range of 68–89% for R89BS,
58–97% for dR89BS, and 6–65% for TritonTM X-100 and Tween® 80. mR89BS, instead,
induced biofilm dispersal at all the tested concentrations with reductions ranging from 80%
to 99%. As confirmed by two-way ANOVA, followed by Tukey post hoc test, the result was
significantly dependent on the type of surfactant and on the tested concentration (p < 0.001).
R89BS and its purified fractions were the most effective: the values of absorbance derived
from the biofilms treated with the biosurfactants at concentrations ranging from 0.12 to
2 mg/mL were significantly different to those obtained with the chemical surfactants
(p < 0.001). TritonTM X-100 and Tween® 80 showed a similar dislodging activity (p > 0.05).
Figure 5. Metabolic activity of S. aureus® 6538TM biofilms after treatment with surfactants. To
evaluate the dislodging effect of surfactants, pre-formed biofilms were co-incubated with increasing
concentrations of the different samples for 24 h at 37 ◦C.
3.7. Anti-Adhesive Activity
To evaluate the anti-adhesive properties of surfactants, SEDs were coated with the
R89BS crude extract, the purified fractions I and II (mR89BS, dR89BS) and the two chemical
surfactants. As confirmed by one-way ANOVA, bacterial adhesion on SEDs was signifi-
cantly dependent on the treatment of surfactants (p < 0.001). In general, surfactant-coatings
efficiently limit the adhesion of S. aureus® 6538TM on silicone surfaces (Figure 6). As shown,
the bacterial cells that adhere on all surfactant-coated SEDs were lower to those that were
present on the controls. After 6 h, with respect to uncoated control SEDs, the pre-treatment
of silicone surfaces with R89BS, mR89BS, dR89BS, TritonTM X-100 and Tween® 80 resulted
in a reduction in cell adhesion of 97%, 97%, 90%, 65% and 58%, respectively. In particular,
as confirmed by Tukey post hoc test, R89BS and its purified fractions showed absorbance
values significantly different to those observed with the chemical surfactants (p < 0.001).
Conversely, no differences were found among R89BS, mR89BS and dR89BS as well as
between TritonTM X-100 and Tween® 80 (p > 0.05).
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Figure 6. Bacterial adhesion on silicone discs. The efficacy of the surfactants surface treatment on
SEDs was evaluated as reduction of S. aureus® 6538TM adherent cells after 6h of incubation at 37 ◦C,
compared to controls SEDs.
3.8. Anti-Biofilm Activity
In general, surfactant-coated SEDs also efficiently counteract S. aureus® 6538TM biofilm
formation up to 72 h. The anti-biofilm activity of surfactant-coated SEDs against S. aureus
biofilm growth was shown in Figure 7 and Figure S1. After 72 h, with respect to uncoated
control SEDs, the pre-treatment of silicone surfaces with R89BS, Tween® 80 and TritonTM
X-100 resulted in a biofilm biomass reduction of 84.6%, 61.5% and 42.3%, respectively
(Figure 7). However, as confirmed by two-way ANOVA followed by the Tukey post-hoc
test, the differences in biofilm development on SEDs was significantly dependent on
the type of surfactant used for the pre-treatment of the silicone surfaces (p < 0.001). In
particular, it was observed that R89BS-coated discs were the most effective in inhibiting
S. aureus biofilm growth, followed by Tween® 80-coated and TritonTM X-100-coated discs.
Conversely, no differences were found among R89BS, mR89BS, and dR89BS (p > 0.05). In
addition, it was interesting to note that the biofilm inhibitory activity of all the surfactants
tested (both synthetic and natural) remained almost constant over time (from 24 to 72 h).
Figure 7. Activity of surfactant-coated SEDs against S. aureus® 6538TM biofilm formation. The anti-
biofilm efficacy of surfactant-coated SEDs was evaluated in terms of inhibition of the total biofilm
biomass after 24, 48 and 72 h of incubation.
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4. Discussion
In this study, an accurate and specific HPLC-MS/MS method has been applied for
the identification and quantitation of rhamnolipids congeners produced by P. aeruginosa.
R89BS crude extract (purity 91.4%) was composed by five mono-rhamnolipids (70.6%)
and three di-rhamnolipids (20.8%) congeners, ranging from C8 to C12 chain length, with
congeners Rha-C10-C10 and Rha-Rha-C10-C10 as the most abundant.
The composition of R89BS crude extract studied at different incubation times shows
that the mono rhamnolipid family was always the most prevalent. In particular, the highest
concentration was observed at five days of incubation, corresponding to the transition to
the stationary phase and reflecting their secondary metabolite behavior. On the contrary,
di-rhamnolipids were almost constant at the three time points. The molar ratio of mono-
and di-rhamnolipids is known to be strain dependent and has been demonstrated to vary
over time [50].
R89BS and its purified fractions showed a high reduction of water surface tension and
low critical micelle concentration. The CMC of rhamnolipids is quite low if compared to
other biosurfactants; however, differences in their surface tension and CMC were reported
with values, respectively, in the range of 72–30 mN/m and of 10.1–500 mg/L [51].
The hydrophilic/lipophilic balance (HLB) values were calculated according to Griffin’s
method for non-ionic surfactants [52]. HLB were 6.5 and 9.5 for Rha-C10-C10 and Rha-
Rha-C10-C10, respectively, as also observed by Diaz De Rienzo et al. [52]. The analysis
of the rhamnolipids produced by Burkholderia thailandensis E264 (Rha-Rha-C14 -C14) and
P. aeruginosa ATCC 9027 (Rha-C10 -C10) had an HLB values of 9.2 and 6.5, respectively [53].
Therefore, R89BS mixture shows an HLB value of 7.2 calculated as a weighted average
by considering the percentage composition of the extract. However, under the condition
tested in this work (pH 7.0), R89BS carboxylic moieties are dissociated. In this case, due to
rhamnolipid ionization, the real HLB value may be higher, increasing its emulsification
activity as confirmed by the E24% index, which was of about 60% in the pH range 7–11 and
zero at lower pH (Table S1).
The antibacterial activity of R89BS, mR89BS, and dR89BS was evaluated in co-incubation
condition and compared with that of commonly used synthetic surfactants, such as Tween®
80 and TritonTM X-100 [54,55].
A minimal inhibitory concentration was detected only for R89BS, mR89BS, and
TritonTM X-100 but not for Tween® 80 and dR89BS. From this experimental evidence,
it is possible to assume that the antibacterial activity of the crude extract is ascribed to the
mono-rhamnolipid fraction. In particular, R89BS and mR89BS were more efficient in killing
S. aureus planktonic cells compared to TritonTM X-100, as confirmed by their higher cell
permeabilization ability. These results suggest that the inhibition subsequently observed
on S. aureus biofilm formation may also depend on the ability of these three surfactants to
affect the pathogen growth.
The antimicrobial activity of rhamnolipids and other types of glycolipids was pre-
viously reported [56–59]. The glycolipid obtained by the marine strain Staphylococcus
saprophyticus SBPS 15 completely inhibited the growth of human pathogens such as
Escherichia coli, Klepsiella pneumoniae, P. aeruginosa, Vibrio cholerae, S. aureus, Candida albicans
at concentrations of 4–64 µg/mL [60]. Sophorolipids (SLs)-grafted gold monolayers showed
biocidal activity against both Gram-positive (Enterococcus faecalis, Staphylococcus epidermidis,
Streptococcus pyogenes) and Gram-negative (E. coli, P. aeruginosa and Salmonella typhymurium)
strains [61].
In addition, R89BS, mR89BS, and TritonTM X-100 were able to strongly decrease
S. aureus cell surface hydrophobicity, which may affect cells ability to adhere to surfaces.
It is known that hydrophobicity of cells can increase the propensity of microorganisms
to adhesion, causing damage to surfaces by biofilm formation, particularly to medical
implants that are constructed from hydrophobic materials such as silicone, stainless steel,
Teflon, etc. [62].
Pharmaceutics 2021, 13, 1172 15 of 20
After comparative analysis of commercial rhamnolipids activity on resistant and
sensitive bacteria, de Freitas Ferreira et al. [63] suggested that these biosurfactants promotes
alterations in proteins, carbohydrates, and membrane phospholipids present on the cell
surface by solubilization and release of apolar membrane components or adsorption of
rhamnolipids on cell surface. These alterations probably cause the observed reduction in
cell surface hydrophobicity, the changes in cell permeability or cell lysis, as confirmed by
scanning electron microscopy.
On the contrary, for Tween® 80 and dR89BS, no minimal inhibitory concentration was
found on planktonic cells in the tested concentration range, suggesting that the inhibition
of biofilm formation as well as the biofilm disintegrating activity observed subsequently
do not depend on its ability to strongly influence the pathogen growth.
All the surfactants showed significant activity against S. aureus sessile cells in co-
incubation experiments, where R89BS was the most efficient. This activity is also defined
as the ability to disrupt pre-formed biofilm [64–66] and it seems to be due to the direct
antimicrobial action of biosurfactants against pathogens but also to cavity formation within
the biofilm structures [67] and/or to the induction of changes in the quorum sensing
signaling and gene expression involved in biofilm growth and dispersal [68–70].
Liu et al. [71] demonstrated that surfactin affected S. aureus adhesion and significantly
promoted biofilm dislodging, decreasing the production of alkali-soluble polysaccha-
rides, the downregulation of icaA and icaD expression, and the alteration of the quorum
sensing system by the regulation of the auto inducer 2 activity. The effect of different
types of rhamnolipids and sophorolipids was also investigated against some oral bac-
terial pathogens such as Streptococcus oralis, Actinomyces naeslundii, Neisseria mucosa and
Streptococcus sanguinis [72,73]. These glycolipids significantly inhibited the formation of
biofilms in a range of 60–90% and dislodge pre-existing biofilms in a range of 50–100%.
The anti-adhesive and anti-biofilm activities of R89BS were evaluated on silicone at
different incubation times and compared to those of TritonTM X-100 and Tween® 80 synthetic
surfactants. Purified fractions containing only mono- (Rha-C10-C10 90.1%) or di-rhamnolipids
(Rha-Rha-C10-C10 96.9%) were also prepared to test their activity in comparison with the
crude extract and to detect which of the two fractions was the most efficient.
R89BS crude extract showed the highest ability to inhibit S. aureus adhesion to silicone
and its activity was not significantly different from that of the mono- and di-rhamnolipid
purified fractions, suggesting that they contribute equally to the anti-adhesive activity of
the biosurfactant. Similarly, the biosurfactant R89BS showed a better ability to inhibit the
formation of S. aureus® ATCC 6538TM biofilm compared to the synthetic surfactants at all
incubation times. Moreover, its efficacy was also confirmed by the fact that the real amount
of R89BS adhered to the silicone surface was only 4.4 µg for disc, as measured through
the HPLC-MS/MS method after washing the coated discs. R89BS coating on silicone, as
confirmed by the previously observed reduction of the advancing and receding contact
angle [45], significantly increased the surface wettability and hydrophilicity preventing mi-
crobial adhesion. As in this study, other research groups demonstrated that biosurfactants
are able to alter the chemical and physical properties of surfaces such as their roughness
and hydrophobicity, counteracting microbial adhesion and biofilm formation [74,75].
TritonTM X-100 and Tween® 80 anti-adhesive activity was almost similar, whereas
TritonTM X-100 had the mildest action at inhibiting the formation of S. aureus biofilm.
Furthermore, the biofilm inhibitory activity of all the surfactants tested (both synthetic and
natural) remained almost constant over time (from 24 to 72 h).
Even if the anti-biofilm activity of glycolipids is well known [72,76–78], in this work,
for the first time, the higher anti-biofilm efficiency of rhamnolipids compared to synthetic
surfactants was demonstrated. Similar results were reported by Pontes et al. [79] on other
glycolipids. These authors compared the ability of a mixture of sophorolipids, produced
by Starmerella bombicola CBS 6009, to prevent biofilm formation of S. aureus and E. coli to
the synthetic surfactants TritonTM X-100 and sodium dodecyl sulfate (SDS). Both synthetic
surfactants showed lower anti-biofilm activity than that of the biosurfactant at 24 h of
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incubation. In addition, similarly to R89BS sophorolipids decreased the hydrophobicity of
the silicone surface, thus limiting biofilm formation of S. aureus and E. coli [79].
Further evidence of the efficiency of R89BS as a coating agent was reported by
Tambone et al. [80]. The rhamnolipid coating significantly inhibited Staphylococcus spp.
biofilm formation on three commercial titanium implant surfaces, leading to a decrease in
terms of biomass up to 98% for S. aureus, and up to 78% for S. epidermidis at 24 h.
R89BS also showed anti-adhesive and anti-biofilm properties against inter-kingdom
dual-species biofilms (S. aureus-C. albicans and S. epidermidis-C. albicans), inducing a re-
markable reduction of biofilm biomass, metabolic activity, viability, and microstructural
architecture, up to 72 h on both polystyrene and silicone surfaces without affecting the
biocompatibility of the material [49].
5. Conclusions
In the present study, the rhamnolipid produced by P. aeruginosa R89 was deeply
characterized and its antimicrobial/anti-biofilm activities compared with commercial
synthetic surfactants, namely Triton X-100 and Tween 80.
Rhamnolipid R89BS, composed of a mixture of mono-rhamnolipids (70.6%) and di-
rhamnolipids (20.8%), showed a high water surface tension reduction, a low critical micelle
concentration, and good emulsification activity, thermal resistance, and pH stability. R89BS
and its purified fraction mR89BS demonstrated antibacterial activity with low MIC values
(0.06 µg/mL and 0.03 µg/mL, respectively).
R89BS mixture inhibited S. aureus adhesion and biofilm formation on medical-grade
silicone more effectively than the synthetic surfactants, up to 72 h incubation.
R89BS mixture and the purified mR89BS were able to alter the S. aureus membrane
permeability more efficiently than Triton XTM-100 and to modify the surface properties
of both cells and silicone, decreasing their hydrophobicity, and therefore the adhesive
properties. Both mono- and di-rhamnolipid fractions showed the same activity of the
crude extract on the S. aureus adhesion, suggesting that time-consuming and expensive
purification and separation procedures are not necessary.
The results obtained, together with the previous observations of biocompatibility
and activity against mono- and dual-species biofilms on silicone and titanium, further
endorse the idea of a possible applicability of these natural molecules as a coating agent to
limit microbial adhesion and the onset of biofilm. In summary, the use of R89BS may be
envisaged as a protective measure and support to antimicrobial therapy, to reduce implant
colonization and mitigate infections related to biomaterials for medical use.
Supplementary Materials: The following are available online at https://www.mdpi.com/article/
10.3390/pharmaceutics13081172/s1, Additional information on R89BS chemical characterization.
Table S1: Effect of pH on R89BS surface tension and E24h%. Figure S1: Activity of purified mono-/di-
rhamnolipids-coated SEDs against S. aureus® 6538TM biofilm formation.
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